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Vascular Care in Patients With Alzheimer Disease With
Cerebrovascular Lesions Slows Progression of White Matter
Lesions on MRI
The Evaluation of Vascular Care in Alzheimer’s Disease (EVA) Study
Edo Richard, MD; Alida A. Gouw, MD, PhD;
Philip Scheltens, MD, PhD; Willem A. van Gool, MD, PhD
Background and Purpose—White matter lesions (WMLs) and cerebral infarcts are common findings in Alzheimer disease
and may contribute to dementia severity. WMLs and lacunar infarcts may provide a potential target for intervention
strategies. This study assessed whether multicomponent vascular care in patients with Alzheimer disease with
cerebrovascular lesions slows progression of WMLs and prevents occurrence of new infarcts.
Methods—A randomized controlled clinical trial, including 123 subjects, compared vascular care with standard care in
patients with Alzheimer disease with cerebrovascular lesions on MRI. Progression of WMLs, lacunes, medial temporal
lobe atrophy, and global cortical atrophy were semiquantitatively scored after 2-year follow-up.
Results—Sixty-five subjects (36 vascular care, 29 standard care) had a baseline and a follow-up MRI and in 58 subjects,
a follow-up scan could not be obtained due to advanced dementia or death. Subjects in the vascular care group had less
progression of WMLs as measured with the WML change score (1.4 versus 2.3, P0.03). There was no difference in
the number of new lacunes or change in global cortical atrophy or medial temporal lobe atrophy between the 2 groups.
Conclusions—Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of WMLs.
Treatment aimed at vascular risk factors in patients with early Alzheimer disease may be beneficial, possibly in an even
earlier stage of the disease. (Stroke. 2010;41:554-556.)
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In addition to medial temporal lobe atrophy (MTLA) andglobal cortical atrophy (GCA), white matter lesions
(WMLs) and (lacunar) infarcts are common findings in
Alzheimer disease (AD). Patients with AD with cerebrovas-
cular lesions (CVLs) have fewer plaques and tangles than
those without, suggesting that cerebrovascular lesions con-
tribute to the dementia syndrome and its severity. WML
increase and new lacunar infarcts occur over time in elderly
subjects and patients with AD.1 Systolic hypertension, being
overweight, and having high triglycerides are risk factors for
increase of cerebrovascular lesions. Vascular risk factors like
hypertension, diabetes, hypercholesterolemia, and being
overweight are associated with an increased risk of AD.
Treatment of cardiovascular risk factors reduces the risk of
stroke and treatment of hypertension reduces the risk of
incident dementia, including AD. Whether treatment of hy-
pertension and other cardiovascular risk factors can prevent
new vascular lesions in patients with AD is unknown. This
study investigates whether an intervention strategy aimed at
several vascular risk factors in patients with early AD with
CVL can prevent additional WMLs and cerebral infarcts to
slow down disease progression.
Methods
Sixty-five patients participating in the Evaluation of Vascular Care in
Alzheimer’s Disease (EVA) Study, a multicenter randomized con-
trolled clinical trial investigating whether vascular care can slow
down dementia progression in patients with early AD with CVL,
were included. This study is described in detail elsewhere.2
Patients were randomized to vascular care (VC) or standard care
(SC). VC consisted of lifestyle interventions (weight loss and dietary
advice in case the patient was overweight, physical exercise, smok-
ing cessation) and medication (38 to 100 mg acetylsalicylic acid, 50
mg pyridoxine, and 0.5 mg folic acid). Hypertension (140/
90 mm Hg) was treated according to a stepped protocol (reducing
salt intake and increasing exercise, diuretic, and, if necessary, a
-blocker or calcium antagonist). Hypercholesterolemia (total cho-
lesterol5 mmol/L) was treated with 40 mg pravastatin. VC patients
were followed 3 monthly to monitor compliance and adjust the
interventions when necessary. SC patients were referred back to their
general practitioner. A follow-up MRI scan was obtained after
2 years.
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Primary outcome parameter was the progression of WMLs and the
occurrence of new lacunar infarcts. Secondary outcome parameters
were progression of GCA and MTLA and the occurrence of new
cortical infarcts.
Subjects underwent a standardized MRI scan, including axial
fluid-attenuated inversion recovery, T1-weighted 3-dimensional
magnetization prepared rapid-acquisition gradient-echo (MPRAGE),
and axial or coronal T2-weighted fast spin echo. All scans were
analyzed using visual rating scales by a single, trained rater (E.R.)
blinded to clinical data and treatment allocation. WMLs at baseline
were rated using 2 semiquantitative scales: the Fazekas scale (range,
0 to 4) and the Scheltens scale (range, 0 to 84 points).3,4 Progression
of WMLs was rated with the modified WML change score (range, 0
to 9), scoring stable (0) or increase (1) in 9 regions.5
GCA was rated using a 4-point scale and MTLA was rated using
a 5-point scale. The intrarater reliability was high (Cohen  0.9 for
WML, 0.9 for GCA, and 0.8 for MTLA).
Group differences at baseline were assessed using Student t test,
Mann–Whitney U test, and 2 or Fisher exact test where appropriate.
The modified WML change score was analyzed using Mann–
Whitney U statistics and was trichotomized into none, medium (1 to
3 points), or severe (3 points) and analyzed with 2 statistics.
Ordinal regression models were used to correct for baseline diastolic
blood pressure and WML severity. The occurrence of new lacunes
and cortical infarcts and GCA progression were analyzed with
Mann–Whitney U and 2 statistics. Progression of MTLA was
dichotomized (any progression versus no progression) and analyzed
using 2 statistics.
Results
Of 123 patients in the EVA trial, 65 (29 [51%] SC versus 36
[55%] VC, P0.62) had a follow-up MRI. Reasons for
missing follow-up MRI were death (n11), inability to visit
the hospital, or inability to lie still. Subjects without
follow-up MRI had more advanced dementia and more
WMLs at baseline, but there were no differences between the
SC and VC groups at baseline (Table 1). The VC group had
less WML progression than the SC group (1.4 [SD 1.63]
versus 2.3 (SD 1.63; P0.03) with a significant linear trend
(P0.009; Figure; Table 2). Correcting for baseline diastolic
blood pressure did not change this effect (P0.02). No
correlation was found between baseline severity of WML and
modified WML change score in the intervention group
(Spearman rho 0.07, P0.70) and when correcting for
baseline Scheltens score, the difference in WML change
score remained significant (P0.03). There was no differ-
ence in new lacunes, new cortical infarcts, MTLA progres-
sion, or GCA progression (Table 2).
Discussion
This study shows that a multicomponent intervention aimed
at several vascular risk factors, including medical and non-
medical interventions, leads to less WML progression in
patients with AD with CVL. This effect could potentially
influence cognitive decline, because CVL in patients with AD
contributes to dementia severity. A possible reason for the
lack of a clinical effect of vascular care in this study
Table 1. Baseline Parameters
Parameter
Standard
Care
(N29)
Vascular
Care
(N36) P
Clinical
Age, mean (SD), years 75.3 (3.9) 76.8 (5.7) 0.24
Sex: female, no. (%) 16 (55.2) 18 (50.0) 0.44
Blood pressure, mm Hg
Systolic 159.7 (23.7) 151.0 (24.8) 0.15
Diastolic 88.0 (13.5) 80.8 (10.2) 0.02
Total cholesterol, mmol/L 5.6 (1.1) 5.9 (1.4) 0.31
High-density lipoprotein, mmol/L 1.6 (0.6) 1.6 (0.6) 0.91
Low-density lipoprotein, mmol/L 3.3 (1.0) 3.6 (1.1) 0.28
Triglycerides, mmol/L 1.5 (0.9) 1.7 (0.9) 0.51
Homocysteine, mol/L 14.6 (5.8) 17.4 (13.0) 0.34
Folic acid, nmol/L 15.6 (7.7) 17.3 (9.6) 0.44
Vitamin B12, pmol/L 293.0 (109) 335.0 (159) 0.24
Smoking, no. (%) 0 (0) 2 (5.5) 0.22
Body mass index, kg/m2 (SD) 27.6 (4.7) 26.0 (4.0) 0.14
Mini-Mental State Examination (SD) 22.8 (3.2) 23.2 (3.4) 0.66
Radiological
WML Fazekas, no. (%)
0 0 (0.0) 1 (2.8)
1 9 (31.0) 13 (36.1)
2 9 (31.0) 16 (44.4) 0.13
3 11 (37.9) 6 (16.7)
WML Scheltens, mean (SD) 18.9 (6.5) 17.2 (7.9) 0.36
GCA, n (%)
0 2 (6.9) 3 (8.6)
1 16 (55.2) 21 (60.0)
2 10 (34.5) 10 (28.6) 0.58
3 1 (3.4) 1 (2.9)
MTLA, mean (SD) 1.7 (0.9) 1.6 (0.8)
Lacunes, n ( %)
0 19 (65.5) 26 (72.2)
1–3 9 (31.0) 8 (22.2) 0.62
3 1 (3.4) 2 (5.6)
Cortical infarct 2 (6.9) 2 (5.6)
Figure. White matter lesion change score in the SC group and
the VC group.
Table 2. MRI Progression of Abnormalities
Standard Care
(n29)
Vascular Care
(n36) P
WML change (SD) 2.29 (1.63) 1.41 (1.33) 0.03
New lacunes, no. (%) 7 (25.0) 5 (15.2) 0.26
MTLA progression, no. (%) 19 (65.5) 25 (69.4) 0.79
GCA progression, no. (%) 6 (21.4) 10 (31.3) 0.29
Richard et al Vascular Care in Alzheimer Disease: MRI Findings 555
 at Vrije on July 11, 2011http://stroke.ahajournals.org/Downloaded from 
population, as described before,2 could be that the disease
was already too advanced in this group. Although dementia
severity was mild in our sample, it is well known that the
neuropathological changes predate the clinical symptoms by
years and the WMLs were already moderately severe in our
sample. Starting a multicomponent intervention aimed at
vascular risk factors earlier, in nondemented elderly subjects,
might slow down progression (or occurrence) of WMLs in a
similar way and help to preserve cognition in elderly subjects.
The small number of lacunes (and larger infarcts) at
baseline and at follow-up precludes a conclusion about the
effect of the intervention on these parameters. Although
hippocampal atrophy and cortical atrophy are associated with
elevated blood pressure, no effect on the progression of GCA
and MTLA was found. The study was, however, not powered
to find such a difference. Although only part of the initial
study population underwent an MRI at 2-year follow-up, the
2 groups were well balanced and no differential dropout
occurred. The accuracy and intrarater agreement of visual
semiquantitative rating of WML is comparably accurate to
quantitative measurements and therefore there was no limi-
tation to our study results.
The higher baseline diastolic blood pressure in the SC
group does not readily explain the observed difference,
because correction for diastolic blood pressure did not change
the effect of the intervention.
The results of this study are encouraging for designing new
intervention trials aiming at several vascular risk factors at an
earlier disease stage or even in subjects who are not demented
yet to prevent dementia or slow down cognitive decline in
early dementia.6
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